Novo Nordisk Reports Improved Results of Oral Semaglutide in PIONEER 9 Study in Patients with Type-2 Diabetes (T2D)
Shots:
- The P-IIIa PIONEER 9 trial involves assessing of Oral Semaglutide (3- 7-14 mg- qd) vs Victoza (0.9 mg liraglutide) vs PBO in 243 Japanese adults in ratio (1:1:1:1:1) with T2D treated with diet and exercise alone or in addition to an oral anti-diabetic drug as monothx
- Results: reduction in HbA1c @26 wks. (1.1%- 1.5% -1.7% vs 1.4% vs 0.1%); greater reductions in HbA1c @52 wks. (0.9%- 1.3%- 1.5% vs 1.1% vs 0.5%); Achieve target treatment (50%- 67% -80% vs 49% vs 12%); reduction in body weight (0.0- 0.6- 2.8 vs 0.4 vs 1.0 kg); safe & well-tolerated
- Semaglutide is an oral qd GLP-1 analogue indicated for reduction in cardiovascular risk and death in T2D patients
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
